SEARCH:   Advanced

Blood, 15 March 2006, Vol. 107, No. 6, pp. 2507-2516. Prepublished online as a Blood First Edition Paper on November 17, 2005; DOI 10.1182/blood-2005-09-3732. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-09-3732v1 107/6/2507    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Notari, M. Articles by Perrotti, D. Search for Related Content PubMed PubMed Citation Articles by Notari, M. Articles by Perrotti, D. Related Collections Neoplasia Oncogenes and Tumor Suppressors Signal Transduction Gene Expression Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation Mario Notari, Paolo Neviani, Ramasamy Santhanam, Bradley W. Blaser, Ji-Suk Chang, Annamaria Galietta, Anne E. Willis, Denis C. Roy, Michael A. Caligiuri, Guido Marcucci, and Danilo Perrotti From the Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, the Division of Hematology/Oncology, Department of Internal Medicine, and The Comprehensive Cancer Center, The Ohio State University (OSU-CCC), Columbus, OH; the School of Pharmacy, University of Nottingham, Nottingham, United Kingdom; and the Division of Hematology-Immunology, Maisonneuve-Rosemont Hospital Research Center, Department of Medicine, Universite de Montreal, Montreal, QC, Canada. Altered mRNA translation is one of the effects exerted by the BCR/ABL oncoprotein in the blast crisis phase of chronic myelogenous leukemia (CML). Here, we report that in BCR/ABL+ cell lines and in patient-derived CML blast crisis mononuclear and CD34+ cells, p210BCR/ABL increases expression and activity of the transcriptional-inducer and translational-regulator heterogeneous nuclear ribonucleoprotein K (hnRNP K or HNRPK) in a dose- and kinase-dependent manner through the activation of the MAPKERK1/2 pathway. Furthermore, HNRPK down-regulation and interference with HNRPK translation-but not transcription-regulatory activity impairs cytokine-independent proliferation, clonogenic potential, and in vivo leukemogenic activity of BCR/ABL-expressing myeloid 32Dcl3 and/or primary CD34+ CML-BC patient cells. Mechanistically, we demonstrate that decreased internal ribosome entry site (IRES)-dependent Myc mRNA translation accounts for the phenotypic changes induced by inhibition of the BCR/ABL-ERK-dependent HNRPK translation-regulatory function. Accordingly, MYC protein but not mRNA levels are increased in the CD34+ fraction of patients with CML in accelerated and blastic phase but not in chronic phase CML patients and in the CD34+ fraction of marrow cells from healthy donors. Thus, BCR/ABL-dependent enhancement of HNRPK translation-regulation is important for BCR/ABL leukemogenesis and, perhaps, it might contribute to blast crisis transformation. (Blood. 2006;107:2507-2516) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L.-C. Chen, C. Hsueh, N.-M. Tsang, Y. Liang, K.-P. Chang, S.-P. Hao, J.-S. Yu, and Y.-S. Chang Heterogeneous Ribonucleoprotein K and Thymidine Phosphorylase Are Independent Prognostic and Therapeutic Markers for Nasopharyngeal Carcinoma Clin. Cancer Res., June 15, 2008; 14(12): 3807 - 3813. [Abstract] [Full Text] [PDF] E. Spooncer, N. Brouard, S. K. Nilsson, B. Williams, M. C. Liu, R. D. Unwin, D. Blinco, E. Jaworska, P. J. Simmons, and A. D. Whetton Developmental Fate Determination and Marker Discovery in Hematopoietic Stem Cell Biology Using Proteomic Fingerprinting Mol. Cell. Proteomics, March 1, 2008; 7(3): 573 - 581. [Abstract] [Full Text] [PDF] A. M. Eiring, P. Neviani, R. Santhanam, J. J. Oaks, J. S. Chang, M. Notari, W. Willis, C. Gambacorti-Passerini, S. Volinia, G. Marcucci, et al. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis Blood, January 15, 2008; 111(2): 816 - 828. [Abstract] [Full Text] [PDF] J. S. Chang, R. Santhanam, R. Trotta, P. Neviani, A. M. Eiring, E. Briercheck, M. Ronchetti, D. C. Roy, B. Calabretta, M. A. Caligiuri, et al. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBP{alpha}-driven myeloid differentiation Blood, August 1, 2007; 110(3): 994 - 1003. [Abstract] [Full Text] [PDF] S. Chu, L. Li, H. Singh, and R. Bhatia BCR-Tyrosine 177 Plays an Essential Role in Ras and Akt Activation and in Human Hematopoietic Progenitor Transformation in Chronic Myelogenous Leukemia Cancer Res., July 15, 2007; 67(14): 7045 - 7053. [Abstract] [Full Text] [PDF] H. Modi, T. McDonald, S. Chu, J.-K. Yee, S. J. Forman, and R. Bhatia Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells Blood, June 15, 2007; 109(12): 5411 - 5421. [Abstract] [Full Text] [PDF] D. Perrotti and P. Neviani From mRNA Metabolism to Cancer Therapy: Chronic Myelogenous Leukemia Shows the Way Clin. Cancer Res., March 15, 2007; 13(6): 1638 - 1642. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020